Pharmaceuticals
Pharma - Formulators
from 1,025 today
Strides reported a steady quarter amid supply chain disruptions, and management reiterated its FY28 revenue targets. We maintain a Buy rating with a target price of Rs1,410 based on strong growth visibility and FCF generation.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
